Trials / Completed
CompletedNCT03463876
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
A Phase II, Single-arm, Open-label Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
Detailed description
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI). Patients with advanced HCC who failed or intolerable to sorafenib will receive apatinib 250mg orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR 1210+apatinib | SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day. |
Timeline
- Start date
- 2018-03-08
- Primary completion
- 2021-03-10
- Completion
- 2021-03-10
- First posted
- 2018-03-13
- Last updated
- 2026-02-17
- Results posted
- 2026-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03463876. Inclusion in this directory is not an endorsement.